Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + irinotecan + cetuximab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cediranib + irinotecan + cetuximab is a three-drug combination therapy evaluated primarily in phase I trials for advanced solid tumors, including metastatic colorectal cancer. **Cediranib** is an oral, potent inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2, -3) and acts as an antiangiogenic agent, reducing tumor blood supply. **Irinotecan** is a topoisomerase I inhibitor (small molecule chemotherapy) that interferes with DNA replication and transcription, leading to cell death. **Cetuximab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand-induced activation and downstream proliferative signaling. When used together, this combination aims to inhibit angiogenesis, disrupt tumor cell proliferation, and overcome resistance to standard chemotherapy, with investigational roles primarily in advanced solid tumors such as colorectal cancer[3].
- Brand names
- Campto
- Other names
- cediranib + irinotecan + cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on cediranib + irinotecan + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + irinotecan + cetuximab.